<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373188</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00098707</org_study_id>
    <secondary_id>NCI-2017-01618</secondary_id>
    <secondary_id>Winship4142-17</secondary_id>
    <nct_id>NCT03373188</nct_id>
  </id_info>
  <brief_title>VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer</brief_title>
  <official_title>Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Pancreatic and Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vaccinex Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal&#xD;
      antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with&#xD;
      stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal cancer&#xD;
      that has spread to the liver and can be removed by surgery. Monoclonal antibodies, such as&#xD;
      anti-SEMA4D monoclonal antibody VX15/2503, ipilimumab, and nivolumab, may interfere with the&#xD;
      ability of tumor cells to grow and spread.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      To evaluate the effect of the anti-SEMA4D monoclonal antibody VX15/2503 (VX15/2503) alone and&#xD;
      VX15/2503 in combination with immune checkpoint inhibitors, ipilimumab or nivolumab, on the&#xD;
      immune profile in the tumor microenvironment and in peripheral blood.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      To extend the previously reported safety profile of single agent VX15/2503 to the combination&#xD;
      of VX15/2503 and immune checkpoint inhibitors, ipilimumab or nivolumab, in patients with&#xD;
      pancreatic and colorectal cancer.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients are randomized to 1 of 4 arms.&#xD;
&#xD;
      ARM I: Patients undergo surgery.&#xD;
&#xD;
      ARM II: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 intravenously (IV) over 60&#xD;
      minutes on day 1. Patients then proceed to surgery 22-36 days after drug administration.&#xD;
&#xD;
      ARM III: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and&#xD;
      ipilimumab IV over 90 minutes on day 1. Patients then proceed to surgery 22-36 days after&#xD;
      drug administration.&#xD;
&#xD;
      ARM IV: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and&#xD;
      nivolumab IV over 60 minutes on day 1. Patients then proceed to surgery 22-36 days after drug&#xD;
      administration.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 90 days and then every 12&#xD;
      weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate treatment effects of the study drugs on tumor cluster of differentiation 8+ (CD8+) T cell infiltration between the treatment groups.</measure>
    <time_frame>Up to 4 years from date of last treatment dose</time_frame>
    <description>CD8+ T cells in tumor samples will be identified by immunohistochemistry and immunofluorescence staining, and we will quantitate the percentage and staining of the cells in the pancreatic and liver tissue with Integrated Cellular Imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events scale version 4.0</measure>
    <time_frame>Up to 4 years from the date of last treatment dose</time_frame>
    <description>Summary statistics will be presented for all safety analyses. Toxicities will be presented as worst toxicity per patient and will be reported as percent toxicity. Adverse events will be classified using MedDRA System Organ Classes and Preferred Terms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Colon Carcinoma Metastatic in the Liver</condition>
  <condition>Colorectal Adenocarcinoma</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Resectable Pancreatic Carcinoma</condition>
  <condition>Stage I Pancreatic Cancer</condition>
  <condition>Stage IA Pancreatic Cancer</condition>
  <condition>Stage IB Pancreatic Cancer</condition>
  <condition>Stage II Pancreatic Cancer</condition>
  <condition>Stage IIA Pancreatic Cancer</condition>
  <condition>Stage IIB Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IV Colorectal Cancer</condition>
  <condition>Stage IVA Colorectal Cancer</condition>
  <condition>Stage IVB Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (surgery)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (VX15/2503, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (VX15/2503, ipilimumab, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (VX15/2503, nivolumab, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-SEMA4D Monoclonal Antibody VX15/2503</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (VX15/2503, surgery)</arm_group_label>
    <arm_group_label>Arm III (VX15/2503, ipilimumab, surgery)</arm_group_label>
    <arm_group_label>Arm IV (VX15/2503, nivolumab, surgery)</arm_group_label>
    <other_name>moAb VX15/2503</other_name>
    <other_name>VX15/2503</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm III (VX15/2503, ipilimumab, surgery)</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>MDX-010</other_name>
    <other_name>MDX-CTLA4</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm IV (VX15/2503, nivolumab, surgery)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Undergo therapeutic conventional surgery</description>
    <arm_group_label>Arm I (surgery)</arm_group_label>
    <arm_group_label>Arm II (VX15/2503, surgery)</arm_group_label>
    <arm_group_label>Arm III (VX15/2503, ipilimumab, surgery)</arm_group_label>
    <arm_group_label>Arm IV (VX15/2503, nivolumab, surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For patients with pancreatic cancer:&#xD;
&#xD;
               -  Stage I-III cytologically or histologically-proven pancreatic adenocarcinoma&#xD;
&#xD;
               -  Cancer confirmed to be surgically resectable, with surgery evaluation with&#xD;
                  planned resection&#xD;
&#xD;
               -  Patients may have prior neoadjuvant chemotherapy, but no neoadjuvant&#xD;
                  chemoradiation&#xD;
&#xD;
               -  No cancer chemotherapy treatment 2 weeks prior to day 2 of treatment&#xD;
&#xD;
          -  For patients with metastatic colorectal cancer:&#xD;
&#xD;
               -  Stage IV histologically-proven colorectal adenocarcinoma&#xD;
&#xD;
               -  Liver metastasis confirmed to be surgically resectable, with surgery evaluation&#xD;
                  and planned resection; may have minimal extrahepatic disease that is determined&#xD;
                  to be resectable&#xD;
&#xD;
               -  Tumor must be confirmed to be microsatellite stable (MSS); if not already&#xD;
                  reported at a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, we&#xD;
                  will be able to perform this at Emory University&#xD;
&#xD;
               -  No prior immunotherapy&#xD;
&#xD;
               -  No cancer chemotherapy treatment 2 weeks prior to day 1 of treatment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500 cells/µL&#xD;
&#xD;
          -  Platelets ≥ 100,000/µL&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL (may receive packed red blood cell [prbc] transfusion)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN&#xD;
&#xD;
          -  Albumin ≥ 3.0 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
          -  Calculated creatinine clearance of ≥ 50 mL/min&#xD;
&#xD;
          -  International normalized ratio (INR) ≤ 1.5; anticoagulation is allowed only with low&#xD;
             molecular weight heparin (LMWH); patient receiving LMW heparin on stable therapeutic&#xD;
             dose for more than 2 weeks or with factor Xa level &lt; 1.1 U/mL are allowed on the trial&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
          -  Female subjects of childbearing potential must agree to use adequate contraception&#xD;
             (e.g., hormonal or barrier method of birth control; abstinence) for the duration of&#xD;
             study treatment and 3 months after completion&#xD;
&#xD;
          -  Male subjects must agree to use adequate contraception (e.g., condoms; abstinence) for&#xD;
             the duration of study treatment and 3 months after completion&#xD;
&#xD;
          -  Female subjects of childbearing age must have a negative serum pregnancy test at study&#xD;
             entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor venous access for study drug administration&#xD;
&#xD;
          -  Determined not to be a surgical candidate due to medical co-morbidities&#xD;
&#xD;
          -  Treatment with chronic immunosuppressants (e.g., cyclosporine following&#xD;
             transplantation)&#xD;
&#xD;
          -  Prior organ allograft or allogeneic bone marrow transplantation&#xD;
&#xD;
          -  Subjects with any active autoimmune disease or history of known or suspected&#xD;
             autoimmune disease except for subjects with vitiligo, resolved childhood asthma/atopy,&#xD;
             type I diabetes mellitus, residual hypothyroidism, psoriasis not requiring systemic&#xD;
             treatment, or conditions not expected to recur in the absence of an external trigger&#xD;
             are permitted to enroll&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration; inhaled or topical steroids and adrenal replacement&#xD;
             doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             autoimmune disease&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, human&#xD;
             immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral&#xD;
             therapy, ongoing or active infection, symptomatic congestive heart failure (New York&#xD;
             Heart Association [NYHA] class III or IV), unstable angina pectoris, ventricular&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Other medications, or severe acute/chronic medical or psychiatric condition, or&#xD;
             laboratory abnormality that may increase the risk associated with study participation&#xD;
             or study drug administration, or may interfere with the interpretation of study&#xD;
             results, and in the judgment of the investigator would make the subject inappropriate&#xD;
             for entry into this study&#xD;
&#xD;
          -  Clinical evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Patients with prior malignancies, including pelvic cancer, are eligible if they have&#xD;
             been disease free for &gt; 5 years; patients with prior in situ carcinomas are eligible&#xD;
             provided there was complete removal&#xD;
&#xD;
          -  Active bacterial or fungal infections requiring systemic treatment within 7 days of&#xD;
             treatment&#xD;
&#xD;
          -  Use of other investigational drugs (drugs not marked for any indication) within 28&#xD;
             days or at least 5 half-lives (whichever is longer) before study drug administration&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to other monoclonal antibodies&#xD;
&#xD;
          -  Non-oncology vaccines within 28 days prior to or after any dose of ipilimumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Wu, MD</last_name>
    <phone>404-778-2670</phone>
    <email>christina.wu@emoryhealthcare.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allyson Anderson</last_name>
      <phone>404-686-1638</phone>
      <email>allyson.anderson@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KJ Lee</last_name>
      <phone>404-778-3173</phone>
      <email>kyungjong.lee@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Innis Usoro</last_name>
      <phone>404-778-2308</phone>
      <email>innis.e.usoro@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Escobar</last_name>
      <phone>678-843-7029</phone>
      <email>alicia.m.escobar@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Christina Wu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

